B4GALT3 (beta-1,4-galactosyltransferase 3) is a glycosyltransferase enzyme that modifies N-linked oligosaccharides on glycoproteins, particularly through β1-integrin glycosylation 12. The enzyme catalyzes the addition of galactose residues to generate poly-N-acetyllactosamine structures and functions primarily in the Golgi apparatus. B4GALT3 demonstrates context-dependent roles in cancer progression. In some cancers like colorectal cancer, B4GALT3 acts as a tumor suppressor, negatively correlating with metastasis, lymph node involvement, and advanced stages by suppressing β1-integrin-mediated cell invasion and migration 2. Similarly, it suppresses extravillous trophoblast invasion during pregnancy by modifying β1-integrin glycosylation and enhancing integrin degradation 1. However, in other malignancies including multiple myeloma, glioblastoma, hepatocellular carcinoma, cervical cancer, head and neck squamous cell carcinoma, and retinoblastoma, B4GALT3 promotes tumor progression, cell proliferation, invasion, and metastasis 345678. The mechanism involves activation of β1-integrin-FAK signaling pathways, modulation of Wnt/β-catenin signaling, and regulation of endoplasmic reticulum stress responses 38. B4GALT3 represents a potential therapeutic target and prognostic biomarker across multiple cancer types.